ICUI Stock Forecast 2025-2026
Distance to ICUI Price Targets
ICUI Price Momentum
10 Quality Stocks Worth Considering Now
Researching ICU Medical (ICUI) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on ICUI and similar high-potential opportunities.
Latest ICUI Stock Price Targets & Analyst Predictions
Based on our analysis of 8 Wall Street analysts, ICUI has a bullish consensus with a median price target of $186.00 (ranging from $178.00 to $209.00). The overall analyst rating is Strong Buy (8.7/10). Currently trading at $144.28, the median forecast implies a 28.9% upside. This outlook is supported by 5 Buy, 1 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Brett Fishbin at Keybanc, projecting a 44.9% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ICUI Analyst Ratings
ICUI Price Target Range
Latest ICUI Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ICUI.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Dec 11, 2024 | Jefferies | Michael Toomey | Buy | Upgrade | $200.00 |
| Nov 13, 2024 | Keybanc | Brett Fishbin | Overweight | Maintains | $209.00 |
| Nov 13, 2024 | Needham | Mike Matson | Hold | Reiterates | $0.00 |
| Oct 15, 2024 | Keybanc | Brett Fishbin | Overweight | Maintains | $198.00 |
| Oct 14, 2024 | Jefferies | Michael Toomey | Hold | Initiates | $183.00 |
| Oct 10, 2024 | Needham | Mike Matson | Hold | Reiterates | $0.00 |
| Sep 12, 2024 | Raymond James | Jayson Bedford | Outperform | Maintains | $190.00 |
| Aug 8, 2024 | Keybanc | Brett Fishbin | Overweight | Maintains | $147.00 |
| Aug 8, 2024 | Raymond James | Jayson Bedford | Outperform | Maintains | $158.00 |
| Aug 8, 2024 | Needham | Mike Matson | Hold | Reiterates | $0.00 |
| Jun 21, 2024 | Needham | Mike Matson | Hold | Initiates | $0.00 |
| Jun 17, 2024 | Raymond James | Jayson Bedford | Outperform | Upgrade | $135.00 |
| Feb 28, 2024 | Keybanc | Brett Fishbin | Overweight | Maintains | $136.00 |
| Feb 6, 2024 | Keybanc | Brett Fishbin | Overweight | Initiates | $134.00 |
| Dec 14, 2023 | CL King | Kristen Stewart | Buy | Initiates | $110.00 |
| May 9, 2023 | Keybanc | Matthew Mishan | Overweight | Maintains | $216.00 |
| Nov 8, 2022 | Raymond James | Jayson Bedford | Market Perform | Downgrade | $0.00 |
| Aug 9, 2022 | Raymond James | Jayson Bedford | Outperform | Maintains | $190.00 |
| Aug 9, 2022 | Keybanc | Matthew Mishan | Overweight | Maintains | $225.00 |
| Aug 8, 2022 | Raymond James | Jayson Bedford | Outperform | Maintains | $208.00 |
Icu Medical Inc. (ICUI) Competitors
The following stocks are similar to ICU Medical based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Icu Medical Inc. (ICUI) Financial Data
Icu Medical Inc. has a market capitalization of $3.65B with a P/E ratio of -29.9x. The company generates $2.38B in trailing twelve-month revenue with a -4.9% profit margin.
Revenue growth is +7.1% quarter-over-quarter, while maintaining an operating margin of +7.3% and return on equity of -5.8%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Icu Medical Inc. (ICUI) Business Model
About Icu Medical Inc.
Develops medical devices for infusion therapy.
The company generates revenue through the sale of its innovative medical devices and systems, focusing on infusion pumps, infusion sets, and needle-free connectors. By targeting hospitals and healthcare facilities, Icu Medical Inc. meets the critical needs of healthcare professionals, enhancing patient safety and efficiency in intravenous therapies.
Icu Medical Inc. is known for its strong emphasis on research and development, which has established its reputation for high-quality medical solutions. The company has a significant impact in various healthcare sectors, including acute care, oncology, and pharmaceuticals, contributing to advancements in global patient care. Its position in the financial market reflects ongoing trends in medical innovation and technology.
Company Information
Sector
Healthcare
Industry
Medical Instruments & Supplies
Employees
15,000
CEO
Mr. Vivek Jain
Country
United States
IPO Year
1992
Website
www.icumed.comIcu Medical Inc. (ICUI) Latest News & Analysis
ICU Medical (Nasdaq: ICUI) will present at the 24th Annual Needham Virtual Healthcare Conference on April 7, 2025, at 8:00 a.m. PT and hold one-on-one meetings that day.
ICU Medical's participation in a prominent healthcare conference could signal growth opportunities and attract investor interest, influencing stock performance and market perception.
ICU Medical (Nasdaq: ICUI) will participate in a virtual fireside chat at the KeyBanc Healthcare Forum on March 19, 2025, at 8:15 a.m. PT, with one-on-one meetings scheduled for the same day.
ICU Medical's participation in the KeyBanc Healthcare Forum highlights its commitment to investor relations and transparency, potentially influencing market perception and stock performance.
ICU Medical, Inc. will hold its Q4 2024 Earnings Conference Call on February 27, 2025, at 4:30 PM ET. Key executives will present, along with analysts from various firms.
The earnings call provides insights into ICU Medical's financial performance, impacting stock valuation and investor sentiment. Analyst participation suggests scrutiny of future growth and strategy.
ICU Medical Announces Fourth Quarter 2024 Results and Provides Fiscal Year 2025 Guidance
1 month agoICU Medical, Inc. (Nasdaq:ICUI) announced its financial results for Q4 2024, ending December 31. Further details on performance were not provided in the excerpt.
ICU Medical's quarterly financial results can impact its stock performance, indicating growth or challenges that may influence investor sentiment and future investment decisions.
ICU Medical (ICUI) reported Q3 earnings of $2.11 per share, surpassing the Zacks estimate of $1.48. This reflects an increase from $1.57 per share in the same quarter last year.
ICU Medical's earnings beat expectations, indicating strong performance and potential growth, which could boost investor confidence and drive stock price appreciation.
ICU Medical, Inc. (Nasdaq: ICUI) will release its fourth quarter 2024 earnings and hold a conference call on February 13, 2025.
ICU Medical's upcoming earnings release and conference call will provide insights into its financial performance, impacting stock valuation and investor sentiment.
Frequently Asked Questions About ICUI Stock
What is Icu Medical Inc.'s (ICUI) stock forecast for 2025?
Based on our analysis of 8 Wall Street analysts, Icu Medical Inc. (ICUI) has a median price target of $186.00. The highest price target is $209.00 and the lowest is $178.00.
Is ICUI stock a good investment in 2025?
According to current analyst ratings, ICUI has 5 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $144.28. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ICUI stock?
Wall Street analysts predict ICUI stock could reach $186.00 in the next 12 months. This represents a 28.9% increase from the current price of $144.28. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Icu Medical Inc.'s business model?
The company generates revenue through the sale of its innovative medical devices and systems, focusing on infusion pumps, infusion sets, and needle-free connectors. By targeting hospitals and healthcare facilities, Icu Medical Inc. meets the critical needs of healthcare professionals, enhancing patient safety and efficiency in intravenous therapies.
What is the highest forecasted price for ICUI Icu Medical Inc.?
The highest price target for ICUI is $209.00 from Brett Fishbin at Keybanc, which represents a 44.9% increase from the current price of $144.28.
What is the lowest forecasted price for ICUI Icu Medical Inc.?
The lowest price target for ICUI is $178.00 from at , which represents a 23.4% increase from the current price of $144.28.
What is the overall ICUI consensus from analysts for Icu Medical Inc.?
The overall analyst consensus for ICUI is bullish. Out of 8 Wall Street analysts, 5 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $186.00.
How accurate are ICUI stock price projections?
Stock price projections, including those for Icu Medical Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
